Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market within a 30-day timeframe [3] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6][7] - Value Score emphasizes identifying undervalued stocks using financial ratios [4] - Growth Score focuses on a company's future earnings and financial health [5] - Momentum Score capitalizes on price trends and earnings outlook changes [6] - VGM Score combines all three styles to highlight stocks with the best overall potential [7] Zacks Rank and Performance - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors [8] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [9] - There are typically over 800 top-rated stocks available, making selection challenging for investors [10] Stock Selection Strategy - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [11] - The direction of earnings estimate revisions is crucial in stock selection, as downward trends can indicate potential price declines [12][13] Company Spotlight: Zoetis Inc. - Zoetis Inc., established from Pfizer's animal health business spin-off, specializes in products for livestock and companion animals [14] - Currently rated 3 (Hold) with a VGM Score of B, Zoetis shows promise for growth investors with a projected earnings growth of 10.9% for the current fiscal year [15] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate increasing to $5.90 per share [15] - With a solid Zacks Rank and favorable Style Scores, Zoetis is recommended for investors' consideration [16]

Core Insights - Zoetis reported Q3 2024 adjusted earnings of $1.58 per share, exceeding the Zacks Consensus Estimate of $1.46, and up from $1.36 in the same quarter last year [2] - Total revenues for the quarter reached $2.39 billion, an 11% increase year-over-year, surpassing the Zacks Consensus Estimate of $2.29 billion [2] Financial Performance - U.S. segment revenues increased 15% year-over-year to $1.35 billion, beating both the Zacks Consensus Estimate and internal estimates [4] - Companion animal product sales in the U.S. rose 18% to $1.07 billion, driven by monoclonal antibody products and key dermatology offerings [5] - Livestock product sales in the U.S. grew 5% to $278 million, primarily due to improved supply of ceftiofur [6] - International segment revenues improved 7% year-over-year to $1.021 billion, exceeding estimates [6] Product Performance - International companion animal product sales rose 7% to $541 million, supported by growth in OA pain products and dermatology products [7] - Livestock product sales internationally increased 7% to $480 million, driven by price increases and customer purchasing timing [8] Future Outlook - Zoetis raised its 2024 guidance for adjusted diluted earnings to a range of $5.86-$5.92 per share, up from the previous range of $5.78-$5.88 [9] - Expected revenues for 2024 are now between $9.2 billion and $9.3 billion, indicating operational growth of 10-11% [9] Market Position - Zoetis holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the coming months [12] - The company has a VGM Score of B, reflecting a balanced growth and momentum outlook [11]

Summary of Zoetis Inc. Conference Call Company Overview - **Company**: Zoetis Inc. (NYSE: ZTS) - **Industry**: Animal Health Key Points and Arguments Market Position and Growth - Zoetis is positioned to sustain above-market growth due to strong secular trends in the animal health industry, particularly in the companion animal segment, which constitutes two-thirds of the company's business [4][3] - The company has a broad portfolio that allows it to capitalize on market expansion, especially in dermatology and parasiticides, where it is a first mover [5][3] Pricing and Volume Dynamics - The company has successfully implemented price increases across its business while maintaining robust volume growth, with volume growth outpacing price growth in both dermatology and Trio products [7][8] - Historical price levels are expected to sustain long-term growth at a rate of 2% to 3%, with current levels slightly higher than this range [8][22] Product Launches and Market Dynamics - Librela, launched in October 2023, is expected to contribute significantly to growth, despite experiencing some destocking dynamics in Q1 2025 [9][10] - The company anticipates strong year-over-year growth for Librela, with a market size of approximately $27 billion and a significant opportunity to treat osteoarthritis pain in dogs [27][26] Competitive Landscape - Zoetis is confident in its ability to defend its market position against new entrants using price strategies, citing the strong demand for its differentiated products [18][12] - The company has seen a shift in its product mix from production animals to companion animals, reflecting changing consumer preferences and increased spending on pet health [36][37] Innovation and Pipeline - The company is focused on expanding its pipeline in areas such as oncology, chronic kidney disease, and cardiovascular health, while also continuing to innovate within existing franchises [42][43] - Life cycle innovations are expected to drive incremental growth across existing franchises, with a strong emphasis on R&D investments [44][45] Financial Strategy - Zoetis prioritizes internal investments to drive organic growth over share buybacks and dividends, although it maintains a consistent dividend growth rate of approximately 20% CAGR over the last decade [46][47] - The company is generating significant cash flows, allowing it to invest in the business while also considering share buybacks when intrinsic value is favorable [47][46] Consumer Behavior and Market Trends - Increased consumer spending on veterinary care, with veterinary CPI rising over 40% since pre-pandemic levels, indicates strong demand for premium products [19][20] - The company has observed a 4% increase in clinic visits for dermatology, suggesting strong consumer engagement and willingness to pay for pet health services [21][20] Conclusion - Zoetis is well-positioned for continued growth in the animal health market, leveraging its strong product portfolio, innovative pipeline, and favorable market dynamics to capitalize on the increasing importance of pet health among consumers [3][4][5]

After growing up with multiple dogs, me and my girlfriend recently bought our own puppy. Our Shiba Inu is now approximately 4 months old. During these 4 months we had to go to the vet a few times for hisGraduated from one of the top business schools in Europe with an MSc in Finance and passed CFA level 1 in May of 2024. I focus on stocks with a strong competitive advantage and a strong management team. I am currently revising my own portfolio and own 9 stocks as well as some ETFs. After revision I aim to ha ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1][2] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [3] Zacks Style Scores Overview - The Zacks Style Scores categorize stocks into four main types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6][7] - Value Score identifies undervalued stocks using financial ratios [4] - Growth Score assesses stocks based on their future earnings and financial health [5] - Momentum Score tracks price trends to capitalize on upward or downward movements [6] - VGM Score combines all three styles to provide a comprehensive evaluation of stocks [7] Zacks Rank and Performance - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors [8] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [9] - There are typically over 800 stocks rated 1 or 2, which can be overwhelming for investors [10] Stock Selection Strategy - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal investment potential [11] - The direction of earnings estimate revisions is crucial in stock selection, as lower-ranked stocks may still face declining forecasts [12][13] Company Spotlight: Zoetis Inc. - Zoetis Inc., established from Pfizer's animal health business spin-off, specializes in products for livestock and companion animals [14] - Currently rated 3 (Hold) with a VGM Score of B, Zoetis shows promise for growth investors with a projected earnings growth of 10.7% for the current fiscal year [15] - The company has seen upward revisions in earnings estimates, indicating positive market sentiment [15][16]

Zoetis Inc. (NYSE:ZTS) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Thank you for taking the time to join us this afternoon. We're very excited to have Zoetis for our next presentation. For those of you who don't know me, I'm Glen Santangelo. I'm the analyst at Jefferies that covers the stock. I cover a number of things in addition to animal health, spec pharma and HCIT. ...

Summary of Zoetis Inc. Conference Call Company Overview - **Company**: Zoetis Inc. (NYSE: ZTS) - **Event**: Jefferies London Healthcare Conference - **Date**: November 20, 2024 - **Participants**: Wetteny Joseph (CFO), Glen Santangelo (Jefferies Analyst) Key Points Financial Performance - **Q3 Revenue Growth**: 14% operational growth in revenue, marking the third consecutive quarter of double-digit growth [2][3] - **Adjusted Net Income Growth**: 15% increase in adjusted net income [3] - **Companion Animal Segment**: Grew approximately 15%, with 8% from volume and 6% from price [5] - **Livestock Segment**: Achieved 11% growth in Q3, indicating strong performance despite broader market growth of 2% to 4% [36] Companion Animal Business - **Dermatology Franchise**: - Grew 16% in Q3, with Apoquel and Cytopoint driving growth [7][8] - Approximately 20 million dogs globally are under-treated for atopic dermatitis, presenting a significant market opportunity [8][10] - Increased awareness and direct-to-consumer campaigns have contributed to growth [8][10] - **Parasiticides**: - Trio product grew 30% year-over-year, with over half of the growth attributed to volume [14][15] - Significant market share gains from both new and existing customers [18] Market Dynamics - **Pricing Strategy**: - Price realization has improved, contributing to higher growth rates [20] - Excluding hyperinflationary impacts, the company expects to maintain pricing at or slightly above historical trends of 2% to 3% [6][41] - **Competition**: - Anticipated competition in dermatology and parasiticides is expected to drive market education and growth [10][13] Future Outlook - **Guidance for 2024**: - Revenue growth guidance raised to 10% to 11% from previous estimates [38] - Anticipated strong year-over-year growth in 2025, despite the impact of the MFA divestiture [41] - **Livestock Business**: - Expected to continue double-digit growth, with adjustments post-divestiture of the medicated feed additives business [36][37] Additional Insights - **Safety Profile**: Ongoing routine discussions with the FDA regarding product safety, with no unusual concerns reported [32][33] - **Market Trends**: Increasing pet ownership and the human-animal bond are driving demand for veterinary care and products [10][11] Conclusion Zoetis Inc. demonstrated robust financial performance in Q3 2024, with significant growth across its companion animal and livestock segments. The company is well-positioned for future growth, supported by strong market dynamics, effective pricing strategies, and ongoing product innovation.

Company Overview - Zoetis Inc. (NYSE: ZTS) is recognized as a global market leader in animal health products, demonstrating a trajectory of slow and steady growth for the foreseeable future [1]. Investment Philosophy - The investment approach emphasizes the importance of compounding, dividend reinvesting, and patient investing through various market conditions to achieve significant rewards [1]. - The strategy includes a mix of steady investments in high-quality assets along with high-risk/high-reward opportunities, underappreciated turnaround plays, and transformative technologies [1]. Personal Background of the Analyst - The analyst identifies as an amateur investor with over 25 years of experience, self-taught without formal education in investing or business, and values learning from others [1]. - The analyst holds a PhD from Brunel University and is also involved in teaching at the college/university level [1].

I upgraded Zoetis (NYSE: ZTS ) to a 'Buy' rating in August 2024, highlighting the company's direct-to-customer strategy and investment in new products. Zoetis delivered a strong growth in Q3 FY24, with 14% year-over-year growth in both revenue and adjusted net income. Notably, their companion animalMore than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specia ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) | --- | -- ...